Hematopoietic stem cell transplantation (HSCT) is the definitive cure for many malignant and nonmalignant diseases. However, delays in immune reconstitution (IR) following HSCT significantly limit the success of transplantation and increase the risk for infection and disease relapse in the transplant recipient. Therefore, ways to measure and to manipulate immune recovery following HSCT are emerging and their success depends directly upon an enhanced understanding for the underlying mechanisms responsible for reconstituted immunity and hematopoiesis. Recent discoveries in the activation, function, and regulation of dendritic cell (DC), natural killer (NK) cell, and T-lymphocyte subtypes have been critical in developing immunotherapies used to prevent graft-versushost disease and to enhance graft-versus-leukemia. For example, regulatory T cells that induce tolerance and NK receptor-tumor ligand disparities that result in tumor lysis are being used to minimize GVHD and tumor burden, respectively. Furthermore, expansion and modulation of immune effector cells are being used to augment hematopoietic and immune recovery and to decrease transplantrelated toxicity in the transplant recipient. Specifically, DC expansion and incorporation into antitumor and antimicrobial vaccines is fast approaching application into clinical trials. This paper will review our current understanding for IR following HSCT and the novel ways in which to restore immune function and decrease transplantrelated toxicity in the transplant recipient. Bone Marrow Transplantation (2005) 35, 835-857.
mune reconstitution; innate and adaptive immunity; immunomodulation; infection; immunotherapy Hematopoietic stem cell transplantation (HSCT) involves eliminating disease in the recipient using cytotoxic therapy in conjunction with donor-derived, normal hematopoiesis and immunity. To this end, hematopoietic stem cells (HSCs) are harvested from bone marrow (BM), peripheral blood (PB), or umbilical cord blood and transplanted into a heavily immunosuppressed recipient. Despite successful homing and engraftment of stem cells into host hematopoietic tissue, donor-derived immune reconstitution (IR) in the transplant recipient may not readily achieve functional maturation until months to years, if at all, after HSCT. In addition, the process of IR is adversely affected by disease-, patient-, and transplantrelated factors including patient age; underlying disease and disease status; transplant type (autologous vs allogeneic), preparative regimen (myeloablative vs nonmyeloablative), and stem cell source; major histocompatibility complex (HLA) disparity resulting in graft-versus-host disease (GVHD); and infection. Together, these factors culminate to blunt immune responses and to increase susceptibility to infection and disease relapse.
Use of therapy directed at immune restoration in the HSCT is in its infancy, as a thorough understanding for the underlying mechanisms responsible for immune aberrancies is lacking (Table 1) . As a result, application of available immunotherapy against infection, malignancy, or both has generally been disappointing. However, new discoveries and techniques are emerging that have the potential to augment or even to restore immune responses in the transplant recipient. The goals of this paper are as follows:
(1) to review immune effector cells and their function as they relate to HSCT; (2) to review IR across transplant regimens and stem cell sources; and (3) to offer potential considerations for modulating or restoring immune responses during HSCT.
The mammalian immune system: recognition, elimination, and tolerance
The mammalian immune system is comprised of the innate and adaptive immune systems and acts as a surveillance system, discriminating self from non-self.
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Immune effector cells (reviewed in Table 2 ) mediating such discrimination are derived from the pluripotent hematopoietic stem cell through hematopoiesis. Lineage commitment (myeloid vs lymphoid) and progenitor cell differentiation is directed by cytokines and cellular growth factors arising from hematopoietic and nonhematopoietic cell sources. 3, 4 Through production of these soluble mediators, immune effector cells likely influence their own development. 5 In general, the innate immune system is derived from myeloid progenitor cells, whereas the adaptive immune system arises from lymphoid progenitor cells. Exceptions to general lineage derivation include subsets of dendritic cell (DC), natural killer (NK) cell, and T-lymphocytes (beyond the scope of this review). [6] [7] [8] Key differentiated innate effector cells include DC, macrophages and monocytes, NK cells, and polymorphonuclear (PMN) cells, while B and T cells comprise cellular adaptive immunity.
Innate immunity is the more primitive, genetically conserved arm and essentially acts as a nonspecific, frontline defense against foreign antigen.
9 Innate cellularmediated immunity is initiated through recognition of pathogen-associated molecular patterns (PAMPs) by germline encoded pattern recognition receptors such as membrane-bound Toll-like receptors (TLRs) 10 and cytosol nucleotide-binding oligomerization domain (NOD) proteins. 11 TLRs are found on the surface of human DC, monocytes, and neutrophils. 12 TLR recognition of these highly conserved PAMPs, such as bacterial lipopolysaccharide (LPS) (TLR-4) and viral RNA (TLR-3), initiates signal transduction pathways that ultimately result in the activation of nuclear factor-kB (NF-kB) and interferon regulatory factor 3. 13 In turn, these transcription factors control production of proinflammatory cytokines like IL-1 and TNF-a and type I interferons (IFN-a and IFN-b), respectively.
The multifunctional roles of DCs continue to be defined. Originally observed as infiltrative skin cells, DCs are now regarded as the most potent antigen-presenting cell (APC) for naı¨ve T cells. As critical APCs, DCs are uniquely positioned to influence innate and adaptive immune responses to infection and malignancy. 14 Distributed throughout the body, immature DCs process foreign antigen, migrate to lymphoid tissue, and stimulate naı¨ve T cells. After pathogen stimulation, DCs undergo functional maturation into three unique phenotypes in mice: myeloid, lymphoid, and plasmacytoid. 15 Humans have two functional DC subtypes, myeloid (mDC) and plasmacytoid (pDC), which produce cytokines depending upon Toll-like surface expression. For example, TLR-3 agonist, poly(I:C), and TLR-9 agonist, CpG, stimulate IFN-a from human mDC and pDC, respectively. pDCs are important in innate antiviral immunity and have also been shown to activate antitumor responses. 16 mDCs are located in tissues where they play integral roles in antigen capture, processing, and presentation. These DC phenotypes can be dramatically increased in vivo and in vitro with cytokine stimulation, 17, 18 an attractive attribute for their expansion and application as antigen-specific immunotherapy against tumor cells and microbial pathogens.
Once stimulated by extracellular (TLR) or intracellular (NOD) antigens, innate immune effector cells produce cytokines using intracellular signaling cascades as reviewed above. In turn, these cytokines amplify the response by activating additional innate immune cells, act directly to eliminate foreign antigen, and instruct a subsequent adaptive response. APCs such as DCs and macrophages are critical mediators between innate and adaptive immunity. 12, 19 For example, bacterial peptidoglycan and LPS Table 1 Immune function following HSCT: what we do not know activation of TLR-2 and -4, respectively, on macrophages and DC, results in IL-12 synthesis, which stimulates IFN-g production in NK cells. 20, 21 IFN-g activates antimicrobial responses, including enhanced phagocytic function, superoxide, and nitric oxide synthesis, and increased synthesis of other monokines and chemokines culminating in a proinflammatory Th1-type adaptive response. 22 Thus, activation of the innate response results in direct antimicrobial effects, in recruitment and activation of additional innate effector cells and, ultimately, in education of the subsequent adaptive response to the foreign antigen ( Figure 1) .
The adaptive immune response results in clonal effector cell expansion and memory for the specific antigen encountered -key attributes distinguishing it from the innate immune response. Adaptive effector cells consist of mainly B-and T-lymphocytes and are derived from a common lymphoid progenitor cell. Specifically, B cells are derived from plasma cells and produce immunoglobulin in the presence (T-cell-dependent) and absence (T-cell-independent) of T-helper lymphocytes. In contrast to CD4 þ T cells, CD8 þ T-cells (cytotoxic T-lymphocyte (CTL)) possess direct cytotoxic roles in eliminating pathogens and maintaining self-tolerance (discussed below). Regardless of subset, T-cell activation requires MHC-dependent antigen presentation in the context of costimulatory signals, all of which are provided by innate APCs. 1, 2 Cellular activation and elimination responses used against infection are also used in eliminating tumor cells 23, 24 ( Figure 1 ). That is, APC activation of a primary Th-1 response results in subsequent CTL activation and cellular responses directed against tumor cells. As a result, donor lymphocyte infusions (DLIs) have been used as salvage therapy mediating graft-versus-leukemia (GVL) responses against recurrent or minimal residual disease (MRD) following HSCT. 25 Alloreactive NK cells have also recently been shown to be important mediators of GVL. While cytotoxic CD8 þ and CD4 þ T cells target HLA class I-and II-restricted antigens, respectively, NK cells attack allogeneic, non-MHC-restricted targets. 26 Specifically, tumor cells lacking self-class I ligands activate NK 
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Antigen processing/presentation 3 3 Direct pathogen killing Representative cytokines: IL-6, -10, -12, TNF-a cell-mediated cytotoxicity, since binding of these HLA class I antigens to surface killer immunoglobulin-like (KIR) receptors normally inhibit NK lysis. 27 Thus, NK-mediated GVL potentially offers selective elimination of residual disease without promoting GVHD. Regardless of immune cell mediator, a final common pathway for tumor cell elimination is apoptosis via antibody-dependent cytotoxicity (ADCC) and antibody-independent (perforin/granzyme and TNF-like factors such as Fas ligand) mechanisms.
Aside from eliminating nonself antigens, the immune system also is responsible for preventing autoreactive cells from triggering immune responses against self-antigens, a process known as tolerance. 28 Specifically, tolerance of T cells plays a predominant role in averting autoimmune and alloreactive processes against self. T-cell tolerance occurs within (central tolerance) and outside (peripheral tolerance) the thymus. A defining role for regulatory T cells (T regs ) in mediating peripheral tolerance is emerging. Specifically, T regs can produce IL-10 and TGF-b that inhibit or suppress other T cells in addition to APC function. 29 These lymphocytes may have a role in preventing alloreactive processes like acute GVHD and have also been implicated in mediating GVL effects. 30 In summary, coordination between innate and adaptive immune effector responses confers protection against foreign pathogens and disease and prevents self-injury against the mammalian host. In order to measure these protective immune responses, various assays have been developed (reviewed in Table 3 ). In general, functional assays for lymphocytes have been the most extensively applied in the transplant setting. For example, techniques for assessing T-cell receptor (TCR) repertoire diversity (eg CD3R spectratyping) and thymic function (eg TCR rearrangement excision circle (TREC) have been critically important in contributing to an understanding for the detrimental effects of GVHD on lymphocyte and thymic dysfunction, respectively (see below).
In contrast to adaptive cell assays, assays for measuring innate effector cell function are generally less applied and developed. As a result, an overall disparity in 31 and reveal a 'real-time' perspective to HSCT and its associated hematopoiesis and immune recovery. 32 
IR following HSCT
Immune recovery following HSCT is a precarious process in which effector cell reconstitution does not necessarily correlate with recovery in cellular function. This discrepancy has been best defined in adaptive IR, as normal absolute lymphocyte count recovery precedes normalization of lymphocyte function as measured by lymphoproliferation and cytotoxicity assays and inducible cytokine profiles. A summary of IR is provided in Table 4 and serves as the basis for the rationale of using potential immunotherapy to target immune restoration following HSCT (discussed below).
Although a comprehensive comparison of IR between adult and pediatric HSCT recipients is beyond the scope of this paper, two significant differences affecting immune recovery between these patient groups deserve mentioning. First, the presence of a thymus greatly impacts the kinetic and functional recovery of adaptive immunity in the pediatric transplant patient. Children have more enhanced recovery of naı¨ve T cells (CD4 þ CD45RA þ ), greater thymic rebound, more diverse TCR, and higher TREC levels than their adult counterparts. [33] [34] [35] Faster CD4 þ recovery has been correlated with better protection against infection in pediatric vs adult T-cell-depleted BMT 36 and overall patient outcome in peripheral blood stem cell transplantation (PBSCT) from HLA-identical siblings or alternative family donors. 37 Second, pediatric patients seem to have less incidence of GVHD when compared to their adult counterparts. As GVHD has profound impact on immune recovery (reviewed below), its decreased incidence in pediatric patients most likely contributes to the faster ) as well as using immunotherapy in pediatric transplant recipients. Therefore, significant insight into the functional capacity of reconstituted immunity and its role in host defense has largely been made from studies of adult patients and are reviewed in the following sections.
Recovery of innate cellular-mediated immunity NK cells. Innate cellular immunity is mediated by NK, PMN, and DC in addition to monocytes and macrophages. Of these innate effector cells, NK cells have been the most extensively studied in the post transplant period. NK cellularity recovers to normal levels within 1-2 months following HSCT, seemingly irrespective of transplant type, stem cell source, patient age, and GVHD. Specifically, CD56
bright CD16 dim cells are the predominant subset in early NK recovery. The CD56 bright subset is associated with highlevel cytokine production, low natural cytotoxicity and ADCC, and potent lymphokine-activated killer (LAK) activity. 7 In contrast, CD56 dim NK cells are low-level cytokine producers, but potent mediators of ADCC, LAK, and natural cytotoxicity. 7 Concomitant recovery in NK cellularity and cytotoxic activity, as measured by lysis against leukemic cell lines (K562) and ADCC against CD19 þ ALL, has been demonstrated in haploidentical transplantation. 40 Early NK lysis has also been detectable in UCB recipients at 1 month post transplant. 41 In contrast to UCB and haploidentical transplant regimens, NKmediated lysis of K562 targets following allogeneic PBSCT 42 and autologous PBSCT 43 is significantly attenuated.
With their seemingly concomitant kinetic and functional recovery following HSCT and their established antimicrobial and antitumor properties, NK cells make attractive targets for potential immune modulation. However, more knowledge of the types of stimulatory and inhibitory receptors 44, 45 found on reconstituted NK cells and of the ability of these receptors to respond to cytokine signals is needed. 46 Granulocytes: PMN cells, macrophages, and monocytes. Like NK cells, donor-derived granulocytes and monocytes recover in the early post transplant period. Specifically, neutrophil recovery precedes monocytes and tissue macrophages. 47 However, unlike NK cells, cellular recovery of myeloid cells is influenced by transplant-related factors such as stem cell source and GVHD, and their functional recovery does not parallel recovery in cellularity. For example, following murine syngeneic transplantation, recipients have full restoration in peripheral counts by 21 days post-BMT, but increased colony-forming units of Pseudomonas aeruginosa. 48 Such heightened susceptibility to infection was observed to coincide with decreased TNFa production by donor-derived tissue macrophages. 48 Similar predisposition to infection is also observed in human transplant patients, in which reconstituted phagocytes have diminished or impaired chemotaxis, superoxide production, and bactericidal activity for at least 2 months following allogeneic BMT, especially in the presence of GVHD. 49 These defects dramatically increase the risk for pyogenic infection 49 and, ultimately, infection-related mortality. Therefore, the need for immunotherapy augmenting phagocytic and accessory cell function is critical.
Dendritic cells. Like other innate effector cells, DCs recover early following HSCT, especially after matched sibling 50 and nonmyeloablative 51 allogeneic HSCT. In autologous HSCT, DC recovery using unselected BM or PB stem cells was three times faster than with CD34 þ -selected cells. 52 Therefore, like granulocyte recovery, manipulations in stem cell source seem to influence the rapidity of DC reconstitution. Unfortunately, a great void in the literature exists with respect to how reconstituted DCs function. 53 Following autologous PBSCT, reconstituted DC function has been shown to have significant antigen-presenting capacity. 43 However, such observations have been made using in vitro DC generated from precursor populations in the PB of transplant recipients. Studies also suggest that early DC recovery may serve to protect the transplant recipient against infection in lieu of adaptive immune recovery. 52, 54 Finally, a crucial role for DC recovery in overall patient survival has also emerged. 55 Therefore, studies addressing the antigen-presenting and cytokine-producing capacities of reconstituted DCs are vital in elucidating how to augment and direct their effector function against residual disease and microbial pathogens.
Despite its early recovery post-HSCT 47 and its established roles in protecting against infection 56 and in influencing the adaptive immune response, 57 innate IR largely remains a mystery. To address this dearth in understanding, studies are needed to define the crosstalk interactions between reconstituted innate effector cells themselves (ie NK3DC) [58] [59] [60] and their adaptive effector counterparts (ie DC3T cell).
14,61 Such knowledge will prove instrumental in elucidating mechanisms of immune dysfunction and their potential targets for immune restoration.
Recovery of adaptive immunity
In contrast to innate reconstitution, the function of adaptive immune recovery has been more extensively studied and defined for both pediatric and adult HSCT recipients. In particular, in vitro B-and T-cell function have been measured across all types of stem cell sources and transplant types. However, assessments of in vivo function for reconstituted B and T cells remain limited to quantitating immunoglobulin levels and DTH responses, respectively, to new and recall antigens. Notwithstanding these limitations, great strides have recently been made in understanding functional recovery of adaptive immunity.
B cells. In general, B-cell reconstitution precedes T-cell recovery and recapitulates B-cell ontogeny in the absence of GVHD. 62, 63 Although B-cell numbers start to normalize by 3 months post transplantation, B-cell function as measured by immunoglobulin production in sera and in vitro to proliferative mitogens for new and recall antigens may take as long as 2 years, particularly for IgA. 64, 65 Such impairment in antibody production has important consequences for revaccination in the HSCT recipient. 66 As delays in IgG2 and IgG4 production may impair T-cell-independent responses to polysaccharide antigens like Streptococcus pneumonia, a leading cause for bacterial infections in the context of GVHD. 67 Similarly, T-cell-dependent antibody production is delayed for at least 1 year after transplantation. 64 Therefore, suboptimal antibody responses likely reflect a combination of impaired B-cell function, delays in critical helper T-cell function, and deficiencies in the B-cell supportive cytokine milieu of the transplant recipient. In order to augment antibody responses in the transplant recipient, novel vaccination strategies including pre-transplantation vaccination of the donor and recipient are currently being investigated. 68 Strategies for supplementing B-cell function in the post-HSCT setting are currently being explored. For example, administration of IVIG to transplant recipients has been attempted to reduce infection-related mortality. Unfortunately, results have generally been disappointing, without demonstrating a decrease in infections and even suggesting an increase in the incidence of VOD in the transplant recipient. 69, 70 Such results may reflect the potential deleterious roles of B cells in causing damage to host tissue. For example, B cells have been implicated as cellular mediators of chronic GVHD. 71 Thus, the use of monoclonal antibodies (MAbs) directed at B cells and their associated cytotoxic cytokines to treat refractory chronic GVHD is emerging 72, 73 (see section on 'immunotherapy').
T cells. T-cell reconstitution differs markedly from B-cell recovery following HSCT. Foremost, T-cell recovery does not recapitulate cellular ontogeny. Thymic-independent peripheral expansion of memory T cells derived from progenitor cells within the graft precedes central or thymicdependent expansion of naı¨ve T cells. Consequently, CD8 þ suppressor T cells predominate in the early post transplant period, causing an inversion of the CD4:CD8 ratio and a decreased pool of naı¨ve T cells (CD4 þ CD45RA þ ) with diverse TCR repertoires. 74 This 'skewed' repertoire significantly limits the transplant recipient's ability to generate effective clonal T-cell responses against microbial pathogens and tumor cells. Since naı¨ve T-cell recovery is associated with polyclonal TCR repertoires and is correlated with TREC levels, TREC-containing thymocytes serve as both markers for TCR diversity as well as overall thymic function in HSCT recipients. 75 T-cell function has been evaluated using peripheral blood monocytes (PBMC) mitogen response and DTH testing. Both are impaired for at least 6-12 months following HSCT, with the degree of impairment being influenced by the stem cell source and presence of GVHD. For example, T-cell mitogen responses in UCBT recipients normalize at 6-9 months post transplant, 41 whereas autologous 43 [77] [78] [79] [80] Along with accelerated and sustained naı¨ve CD4 þ recovery, 77, 78, 80 improved in vitro proliferative responses 78, 80 have been measured following PBSCT. These results suggest improved anti-infective properties of reconstituted immunity following PBSCT. In the setting of allogeneic HLA-matched sibling transplant, recipients receiving PBSC had lower rates of documented bacterial and fungal infection and lower infection-related death than BMSC recipients. 77 Although no significant differences between fungal and viral infections were noted between autologous PB and allogeneic BM transplant recipients, 79 auto-PB recipients had fewer febrile days, required less antibiotics and blood products, and were discharged earlier than their autologous and allogeneic BMT counterparts. 81 Rates of life-threatening opportunistic infection were similar between pediatric UCB and age-/GVHD-matched sibling-donor BM recipients. 82 Both UCB and BM patients had skewed TCR repertoires and low TREC levels during the first year post transplant; however, UCB patients had higher naı¨ve CD4 þ T cells, TREC levels, and TCR diversity after 2 years post transplant despite receiving lower CD34 þ cells. In contrast, when compared to HLAmatched unrelated donor allogeneic transplantation in adults, UCB recipients had higher infection rates during the first 50 days post transplant and greater overall bacterial infections attributed to delayed PMN cell and lymphocyte recovery. 83 Stem cell mobilization. Despite the seemingly advantageous benefits for using mobilized PBSC, potential deleterious effects on hematopoiesis and immune restoration exist. Granulocyte colony-stimulating factor (G-CSF) mobilization yields higher number of progenitor- 84 and lineage-committed cells, most notably T cells and monocytes, 85 in the graft. In addition, G-CSF has been shown to increase activation markers on these mobilized cells. 86 Once activated, monocytes in the graft can inhibit T-cell function 87, 88 via IL-10 production. 89 Consequently, a shift toward Th2 cytokine production occurs post transplant and may be advantageous for reducing acute GVHD, 90 in which Th1-producing cytokines cause cytotoxic damage to host tissues. 91 However, in the context of high numbers of donor T cells infused within the graft, G-CSF pretreatment may induce chronic GVHD in the transplant recipient. 92 Aside from issues concerning GVHD, G-CSF may alter host defense responses to infection by preferentially inducing a Th2 response and inhibiting recovery in IL-12 production. 93 Thus, macrophage activation, immunoglobulin production, and support for CD8 þ effector T cells may be blunted, increasing susceptibility to bacterial and viral pathogens. 94 In addition to inducing chronic GVHD and immune effector cell dysfunction, cytokine mobilization may adversely effect hematopoietic stem cell engraftment. For example, flt3 ligand (FL) has been shown to mobilize hematopoietic progenitor cells 95 and to increase donorderived DC and NK cell recovery in the transplant recipient. 96 However, FL pretreatment in donor mice resulted in reduced engraftment of purified hematopoietic stem cell (HSC) when transplanted into syngeneic recipients. 97 Although the exact mechanism is unknown, changes in HSC commitment resulting in increased susceptibility to radiation, reduced pluripotency, or both have been postulated.
Graft manipulation. Manipulations to stem cell grafts in order to decrease disease relapse or to prevent GVHD have included ex vivo purging or selecting for CD34 þ SC and depleting T cells, respectively. A limited number of studies address these effects of graft manipulation on subsequent immune recovery. Ex vivo purging of malignant cells in pediatric neuroblastoma (NBL) patients is associated with delays in neutrophil recovery, but otherwise is not associated with further delays in B-and T-cell quantitative and functional recovery when compared to immune recovery with unpurged, autologous BM and PB. 98 Autologous BM grafts purged of NBL and AML cells were similarly associated with delays in lymphoproliferative mitogens responses without documented life-threatening infections. 99 One possibility for the observed delays in immune recovery following malignant cell purging is direct cytotoxicity to the stem and progenitor cells caused by the purging agent, as has been shown with 4-hydroxycyclophosphamide. 100 Therefore, ways to prolong stem and progenitor cell longevity within purged grafts might prove to be beneficial.
CD34 þ selection has also been attempted to lessen the risk of disease recurrence in the autologous setting and to decrease transplant-related mortality in the allogeneic setting. However, significant infectious sequelae have been associated with its use, namely viral infections in the early post transplant period. 101 When compared to 273 patients who received unselected autologous PBSCT, 32 patients receiving CD34 þ auto-PBSCT had more non-CMV viral and bacterial infections. 102 Although impaired T-cell recovery has been implicated for this increased risk of infection, Peggs and colleagues 103 have demonstrated similar lymphocyte subset recovery and TCR diversity between CD34 þ -selected and CD34 þ -unselected auto-HSCT recipients. Therefore, T-cell dysfunction and abnormalities in other immune effector cells seem possible, although other unknown adverse effects of using purified CD34 þ cells are also likely. 104 Finally, T-cell depletion (TCD) in allogeneic HSCT decreases risk for GVHD by dramatically impeding T-cell recovery, irrespective of SC source, but is associated with significant risk of infection and disease relapse. 105 CD34 þ selection has also been combined with TCD in the allogeneic setting to reduce GVHD. Eyrich and colleagues 106 compared IR in 13 pediatric patients who received highly purified CD34 þ PBSC grafts that also were TCD with recovery after conventional MSD-BMT in 12 patients. With respect to T-cell reconstitution, recovery in cellularity and proliferative response was significantly delayed in the CD34 þ group compared to the BMT group for the first 100 days following HSCT. In addition, the CD34 þ group had over-representation of memory CD4 þ CD45RO þ and more skewed TCR repertoires. Despite faster B-cell recovery, CD34 þ recipients had impaired pokeweed mitogen responses than BMT recipients. No significant differences between groups were noted in NK recovery or incidence of fatal infection. Therefore, like autologous transplant recipients, allogeneic patients receiving CD34 þ grafts are highly immunosuppressed for significant periods of time. 107 Autologous vs allogeneic stem cell transplant. Autologous HSCT is not affected by GVHD or the immunosuppressive therapy used to prevent or treat GVHD in the allogeneic setting. Therefore, autotransplant provides direct insight into mechanisms involved in IR without the confounding effects of GVHD immune recovery. Although not influenced by GVHD, the engraftment potential of autologous HSCs likely differs from allogeneic HSCs collected from a healthy donor. First, autologous HSCs are exposed to cytotoxic therapy 108 that likely shortens their lifespan and distorts their homing potential when compared to allogeneic donor HSCs. In addition, differences in BM environment, including stromal cells and cytokine milieu, 109 likely occur between allogeneic and autologous transplant recipients. Together, such factors likely contribute to the impaired IR seen in autologous transplant recipients, thereby increasing their risk for infection and disease relapse. 110, 111 As an example, delays in lymphocyte cellular recovery and function have been measured in both adult 43 and pediatric 76, 98 autologous HSCT recipients and implicated in post transplant sequelae including MRD and opportunistic infection 112 as well as overall survival.
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In contrast to autologous HSCT, allogeneic HSCT has the advantages of therapy-naı¨ve, donor-derived hematopoiesis and IR. In addition, alloreactive responses occur, which may be helpful (GVL) or deleterious (GVHD) to the allogeneic recipient. However, these dichotomous responses are often difficult to separate in the post-HSCT setting and have major implications in transplant-related morbidity and mortality. Furthermore, allogeneic HSCT is also associated with significant infectious sequelae, particularly as a result of GVHD and its associated immunosuppressive prophylaxis. 113 Conditioning regimens: nonmyeloablative and haploidentical. Alternatives forms of HSCT including nonmyeloablative and haploidentical conditioning regimens are increasingly being used to circumvent limitations associated with conventional or myeloablative allogeneic HSCT, namely transplant-associated toxicity and availability of HLA-matched donors, respectively. In principle, these novel forms of HSCT share a common intent of using donor-derived hematopoietic cells and residual recipient cells to augment GVL, while decreasing severity of GVHD and life-threatening infection. [114] [115] [116] The resulting 'mixed' chimerism in the HSCT recipient may prove a novel target for immunotherapy directed to augment function in donorand recipient-derived immune effector cells (discussed later in section on 'immunotherapy').
Although limited, studies comparing immune recovery following myeloablative and nonmyeloablative regimens have been insightful. Maris and colleagues 117 compared immune recovery for one year post transplant in 51 patients receiving HLA-identical PBSCT following nonmyeloablative conditioning (TBI7fludarabine) with a reference group of 67 myeloablated recipients. Nonmyeloablated patients received mycophenolate mofetil for 28 days and cyclosporine until day 35 or 56. Both regimens had similar recoveries in total and subset-specific lymphocytes, in lymphoproliferative responses to viral stimulants, and in total and pathogen-specific antibody levels. Overall infection rates were significantly lower in nonmyeloablated patients, who also had lower rates of CMV infection coinciding with greater numbers of CMV-specific T cells at days 30 and 90. Interestingly, although they had significantly lower rates of infection during the first 90 days post transplant, nonmyeloablated patients, especially those receiving fludarabine, had higher infection rates due to bacterial infections later in the post transplant period. In contrast, Saito and colleagues 118 did not find significant differences in infection rates between nonmyeloablated patients, given 2-CdA, busulfan, and rabbit ATG as a conditioning regimen, and myeloablated patients, despite the former having significantly lower total, naı¨ve and memory CD4 þ T cells. However, differences in conditioning regimens between these two studies may account for the disparate results in infection rates. Together, these studies suggest that nonmyeloablative regimens may confer protection against infection by both reducing toxicity (mucositis) and myelosuppression (neutropenia) and enhancing recovery in functional immune effector cells. 119 Regardless of their advantages, nonmyeloablative regimens are still associated with significant infectious morbidity. [120] [121] [122] Few studies address immune recovery following haploidentical transplantation. Handgretinger and colleagues 40 measured lymphocyte reconstitution in 38 children receiving megadose purified CD34 þ cells harvested from haploidentical parents (n ¼ 24) and matched unrelated donors (n ¼ 14). Haploidentical transplant recipients had faster recovery of B, T, and NK cells compared to their MUD counterparts. With respect to NK cell recovery, haploidentical recipients had unique expansion of CD56 þ / CD158 þ NK cells and early cytotoxicity against HLA class I-negative leukemic cell line K562, which could be augmented with IL-2 post transplant immunotherapy. However, cytotoxicity of fresh leukemic blasts was minimal, most likely due to high HLA class I expression on blast cells. Yet, reconstituted NK cells were able to lyse fresh CD19 þ ALL blasts via HLA-independent ADCC. In 30 adult patients receiving haplo-TCD BMT, Lamb and colleagues 123 also measured early recovery in NK cells, with B and T cell recovery occurring significantly later at 6 months and more than 2 years post transplant, respectively. In addition to delays in lymphocyte numbers, mitogens responses were also delayed for at least 1 year following haploidentical transplant. Together, these studies suggest that NK cellularity and function recover early following haploidentical transplant and may be targets for post transplant immunotherapy.
Mechanisms of immune effector dysfunction and their implications
Without argument, research from the last two decades has enlightened us to key effector cells and cytokines participating in immune recovery following HSCT. However, a complete picture of how these individual participants function to generate a collective response in the transplant recipient remains incompletely defined. In vivo responses to microbial challenge exemplify how little is actually known about reconstituted immune responses in the post transplant period. That is, reconstituted pathogen-recognition receptor activation and signaling, cytokine-and chemokine-mediated cellular regulation, and accessory-cell antigen presentation and function remain largely unexplored. Even less is known about how each reconstituted arm of the immune system interacts and influences the other. Thus, studies addressing these responses in the HSCT recipient are vitally necessary for the successful application of immunotherapy ameliorating reconstituted effector cell dysfunction.
Mechanisms for T-cell dysfunction have been defined more so than for any other immune effector cell. In particular, the deleterious effects of acute GVHD on T-cell function are the best established. GVHD further inhibits T-cell recovery through T-cell apoptosis via activationinduced cell death, 124, 125 through immunosuppressive cytokine production by regulatory cell populations (eg TGF-b and IL-10), 126 and through direct damage to thymic epithelium and stroma. 127 Such thymic damage has been assessed by measuring TREC or T-cell rearrangement excision circles in thymic emigrants 128 and GVHD is associated with decreases in TREC-containing thymocytes. 129 GVHD seems to adversely affect all levels of Tcell function, from delaying T-cell ontogeny 75 and limiting TCR diversity 82 to impairing cytokine production in reconstituted T cells.
Other known mechanisms of impaired T-cell recovery include monocyte-mediated inhibition in the context of G-CSF stem cell mobilization, 130 monocyte-mediated apoptosis via FasL expression, 131, 132 activation-induced apoptosis, 125 inhibition of supportive cytokines such as IL-2, 133 and altered signal transduction. 134 Variations on these themes most likely result in altered function of other reconstituted immune effector cells. 135 However, such mechanisms of immune dysfunction post-HSCT currently remain largely undefined. 136 Nonetheless, consequences of immune dysfunction in the HSCT recipient include delayed engraftment or even graft failure, disease relapse, and infection. Finally, aberrant allo-and autoimmune reactions are most likely perpetuated in the HSCT recipient, in whom regulatory and suppressor cells are either absent or dysfunctional.
Immunotherapy

Overview
Effective application of immunotherapy is currently hindered by limitations in our understanding for the underlying mechanisms responsible for immune dysfunction following HSCT (Table 1 ). For those mechanisms we do understand, significant overlap of common effector cells, cytokines, and chemokines often exist, such that specificity for a desired response (ie GVL) is not easily attainable and may even result in an undesirable consequence (ie GVHD). Equally as crucial as defining these mechanisms of immune dysfunction is increasing our understanding for the pharmacology of established and proposed immunotherapies. That is, we know very little about how to administer immunotherapy, especially in the context of HSCT, given that pharmacokinetic (administration and metabolism) and pharmacodynamic (desired and adverse effects) aspects of immune therapies are largely unknown. 137 Furthermore, HSCT recipients are a heterogeneous patient population, who likely will have unique responses to interventions based upon previous therapy, comorbidity, age, and other underlying physiologic and genomic differences. [138] [139] [140] [141] Finally, when to administer the immunotherapy is also not fully appreciated, as the timing of immunomodulation during immune effector cell recovery likely has important implications. 142 In short, the holistic 'context' of applying immunotherapy must be appreciated before clinical success is achieved.
Notwithstanding these impediments, success in immunotherapy during HSCT continues to evolve. Obvious targets for immunotherapy include immune effector cells themselves, their targets, or the responses they elicit. Other potential cellular targets include hematopoietic stem and progenitor cells and mesenchymal stem cells. Like their cellular targets, soluble mediators such as cytokines and novel factors like heat-shock proteins (HSPs) and TLR agonists have also been used to affect immune responses. Finally, combinations of these cellular and soluble forms of immunotherapy are currently being explored to promote desirable responses or to avoid undesirable ones in the HSCT recipient (reviewed in Table 5 ).
Cellular factors
Cellular factors are attractive targets for immunotherapy given their established roles in hematopoiesis, host defense, and immunomodulation (reviewed in Table 2 ). In general, forms of cellular immunotherapy include expansion of beneficial cell types and depletion of harmful effector cells. Examples of these cellular forms of immunotherapy pertinent to immune restoration are discussed below.
Expansion: adoptive transfer and vaccination. DCs, 143, 144 NK cells, 145, 146 and cytotoxic lymphocytes 25 have been shown to mediate antitumor responses in the HSCT recipient. Specifically, these cells have been incorporated into vaccines or expanded and directed against tumor cells (adoptive transfer). Such antitumor responses likely involve APC activation and induction of a Th1-predominant response, in which CTL-mediated tumoricidal responses are generated. 23 However, tumor cells utilize 'escape mechanisms' to evade lymphocyte-mediated cytotoxicity including downregulation of activation receptors, costimulatory molecules or HLA class I antigens recognized by CTLs; release of soluble factors like IL-10 and TGF-b that inhibit T-helper cells, CTLs, and APCs; and altered FAS-L expression on tumor cells that render them resistant to apoptosis (reviewed in Kolb 147 ). Therefore, successful application of vaccine immunotherapy directed against tumor cells must be able to circumvent these obstacles. Examples of countermeasures to enhance vaccine efficacy include the use of adjuvant therapies like HSPs, 148 CpG oligodeoxynucleotides, [149] [150] [151] and GM-CSF 152 to augment cytotoxicity; the use of cytokines to redirect DC-mediated T-helper responses; 153 and the use of gene-transferred factors to increase lymphocyte recruitment and to concentrate responses within the tumor. 154 Notwithstanding these novel techniques, impediments to the success of adoptive transfer of ex vivo-expanded effector cells or their being incorporated into vaccines exist. First, survival of expanded effector cells is limited due to factors intrinsic to the cells themselves (eg replicative senescence) or to the host in which the cells are infused (eg regulatory and suppressor cell-induced apoptosis of expanded effector cell). Second, induced alterations in the immune cellular phenotype through expansion or antigen loading may adversely affect antitumor potency, as seen with DC maturation stages correlating with tumor immunity. 155 Third, soluble factors associated with the tumor such as VEGF may inhibit DC production and function. 156 Finally, factors intrinsic to HSCT may also affect antitumor responses. For example, DLI has recently been applied to the setting of nonmyeloablative transplant, in which transplant recipients achieve a state of mixed hematopoietic and immune chimerism. 157, 158 Using a murine model of TCD BMT and T-cell leukemia/lymphoma (EL4), Mapara and colleagues 159 have shown that GVL is actually stronger in this mixed chimeric setting than the when full chimerism is achieved. Furthermore, mixed chimerism did not cause GVHD if two preconditions were met: (1) DLI was delayed for enough time to allow recovery from tissue-damaging inflammation and subsequent T-cell migration and (2) alloreactive T cells were absent from the initial donor graft. Whether such separation of GVL and GVHD effects can similarly be demonstrated in non-TCD, human HSCT remains to be seen, as timing of vaccine administration is likely critical in order to separate these dichotomous alloimmune responses. 142 Given these limitations, strategies have been employed to enhance the function of adoptively transferred cell populations. For example, administration of IL-2 has been shown to benefit patients who have failed DLI. 160, 161 Therefore, coadministration of IL-2 with DLI might enhance donor T-cell function in order to augment GVL responses in the transplant recipient. Similar in concept but further along in clinical application is the administration of ex vivo activated T cells. In a phase I study of autologous SCT using CD3 and CD28 antibody-coated beads to collect and simultaneously stimulate T cells, Laport and colleagues 162 have shown that infusions using these T cells into patients with refractory or relapsed NHL is feasible, results in enhanced lymphopoiesis, and increases antitumor T-cell function as measured by ex vivo IFN-g production.
In addition to antitumor responses, immune effector cell expansion can also be used to confer anti-microbial responses. For example, ex vivo-expanded, antigen-specific CTLs are promising clinical alternatives to failed antiviral therapy [163] [164] [165] or viral-associated malignant disorders recalcitrant to conventional chemotherapy. 166, 167 Similarly, DCs have been used in vaccines against fungal pathogens like aspergillosis 168 and may hold promise in priming pathogen-specific CTLs. 169, 170 Like DCs and T-lymphocytes, NK cells mediate antitumor and anti-microbial responses. 171, 172 For example, NK cells have been shown to mediate GVL effects via recognition of HLA class I antigens on tumor cells, while decreasing incidence of GVHD in nonmyeloablative and haploidentical transplantation. 27, 173 Therefore, expansion and infusion of NK cells specific for tumor and microbial antigens into transplant recipients would be a novel alternative to DC-and CTLbased therapies. 174 Furthermore, incorporation of NK cells into antitumor or anti-microbial vaccines may have important implications in mediating vaccine effect. 175 However, caution in the use of NK cell adoptive transfer is warranted, as NK cells have been shown to mediate effects of GVHD. 176 Likewise, beneficial antitumor effects of NK cells may be restricted to nonmyeloablative and haploidentical transplant settings. 177 T cells have beneficial roles like protection against infectious pathogens and residual tumor, but also cause deleterious responses like GVHD in the HSCT recipient. Regulatory T cells (T regs ) are a distinct population from helper and CTLs with immunomodulatory effects that reduce alloreactivity and GVHD in the HSCT patient. 178 Early studies addressing expansion of T regs in humans are encouraging. 179 If successful, expanded T regs could be used to attenuate cytotoxic alloreactive reactions in the transplant recipient. However, successful expansion of this small effector cell population, enhancing its suppressor potential, 180 and utilizing its effects outside of acute GVHD 181 may prove difficult. Notwithstanding, successful expansion and transfer of T regs into the allotransplant host could be used to augment GVL, attenuate GVHD and risk of infection, and ultimately reduce transplant-related morbidity and mortality. HSCs and lymphoid and myeloid progenitor cells seem obvious targets for immunotherapy. However, success in ex vivo expansion has been disappointing, likely reflecting both an inability to study these cells outside of their natural microenvironment 182 and an incomplete understanding of how these cells are regulated. 5 Nonetheless, a literature addressing the immunomodulatory effects of progenitor cells is emerging. For example, murine myeloid progenitors have been shown to confer protection against bacteria and mold infection 183 as well as to attenuate alloreactive responses like GVHD. 184 Similarly, murine lymphoid progenitor cells have also been shown to confer protection against infection, specifically CMV. 185 As these cells are derived from HSCs, further study of these progenitor cells and their immunomodulatory effects may reveal novel ways of HSC regulation and alternative approaches to their expansion.
Mesenchymal stem cells (MSCs) are nonhematopoietic progenitors that give rise to adventitial and other stromal cells in the marrow responsible for fabricating the connective tissue scaffolding and for producing cytokines, chemokines, and extracellular matrix proteins that regulate hematopoietic homing and proliferation. 186 In addition to their effects on HSC proliferation and engraftment, 187 MSCs have been shown to inhibit T-cell alloreactivity. 188, 189 Therefore, successful expansion of MSCs 190 and transfer into HSCT recipients could potentially be used to ameliorate cytotoxic damage to the BM, 191 to enhance HSC engraftment and hematopoiesis, or to attenuate or redirect alloreactivity like GVHD. 192 Depletion. The goal of cellular depletion is to attenuate or to avoid entirely the adverse effects associated with a specific effector cell. The removal of T cells from the stem cell graft is the most common form of cellular depletion used to decrease the incidence of GVHD. Ex vivo methods of TCD include complement lysis (Campath-1 G/H/M), immunomagnetic separation, soybean agglutination, and red cell e-rosetting. Owing to their ease of administration, MAbs directed against IL-2R are currently being used in the ex vivo 193 and in vivo 194, 195 settings to replace these other laborious and expensive techniques. However, significant adverse effects are associated with the use of TCD grafts including graft failure, delayed IR, and relapsed disease. 105 Alternative forms of TCD like CD34 þ selection (reviewed in section on 'graft manipulation') and selective CD8 þ purging are being utilized to minimize these adverse effects. In a pilot study in which they depleted CD8 þ cells from DLI apharesis products using the Eligix CD8-HDM cell Separation technology, Alyea and colleagues 196 have demonstrated that CD8-depleted infusions were still capable of GVL responses while minimizing GVHD (1/9 patients). In a haploidentical murine model, Hsieh et al 197 infused LLME-treated (depletion of perforin-containing alloreactive T cells) splenocytes into transplant recipients that demonstrated minimal GVHD, but preserved GVL responses. However, the use of LLME technology in human subjects has been associated with graft failure (1/ 19 patients) and GVHD (4/18 patients). 198 Finally, CD34 selection using the CliniMACS system has been applied to patients at high risk for development of GVHD (age, unrelated, or mismatched stem cell source, haploidentical transplant) and found to have a graft failure rate B10%. 199 However, significant infectious morbidity mainly due to opportunistic infection continues to be seen despite donor DLI. 200 Therefore, using soluble factors to enhance effector cell function may potentially decrease such infectiousrelated morbidity and even disease relapse.
Soluble factors and their targets
Soluble factors such as cytokines and their associated MAbs are the most common form of immunotherapy used in the pre-and post transplant setting and have been applied in a variety ways to affect different levels of effector cell development, activation, localization, and response. In addition to these direct effects on immune cells, soluble factors have also been used to decrease malignant burden in the setting of HSCT -an important means of facilitating hematopoiesis and immune restoration in the HSCT recipient, but beyond the scope of this manuscript (see excellent reviews by Harris 201 and Wasil 202 on this topic). Therefore, soluble forms of immunotherapy targeting immune restoration during HSCT will be discussed in the following sections.
Hematopoiesis and stem cell mobilization. Cytokines have been used to expand both hematopoietic progenitor cells 203 and differentiated immune effector cells. 204 The cytokine with the most clinical experience in the setting of HSCT is G-CSF, which has been used to mobilize stem cells, to accelerate hematopoiesis, and to decrease infectious burden in the transplant recipient by accelerating neutrophil recovery. 205 However, potential deleterious effects include alteration in T-cell function and induction of chronic GVHD (reviewed in section on 'stem cell mobilization'). In addition, G-CSF has been shown to inhibit immune cell function of stem cell harvests. Specifically, Joshi and colleagues 206 compared ex vivo mononuclear cell (MNC) function from G-CSF-mobilized stem cell harvests in healthy donors with MNC function from nonmobilized healthy donors and found that cytokine-mobilized effector function was significantly impaired. Specifically, cytotoxicity of NK and LAK cells and B-and T-cell mitogen responses were less in mobilized MNCs than those measured in nonmobilized cells. These results have major implications for the influence of cytokine-mobilization regimens on donor-derived immunity pre-and post-stem cell infusion, an area in transplant immunology requiring further study.
FL mobilizes stem cells and expands both progenitor 207 and differentiated immune effector cells, particularly NK 154 and DCs. 208 Furthermore, endogenous FL has been shown to correlate with DC and NK recovery in the allogeneic transplant setting. 96 Unlike G-CSF, less is known regarding effects of FL on the stem cell graft, although it clearly influences alloreactive responses relevant to allogeneic HSCT, as demonstrated by its ability to induce GVHD when administered to transplant recipients, but to reduce the incidence of GVHD when used to mobilize stem cells in the donor. 209 Such disparate effects likely reflect the cytokine's selective expansion of certain effector cell phenotypes 96 and its ability to modulate the activation of alloreactive effector cells. 210 These preferential cytokine effects also seem to apply to FL's influence on stem cell mobilization and subsequent engraftment, as FL-mobilized HSCs harvested from PB demonstrate enhanced engraftment when compared to stem cells harvested from BM. 97 Together, these studies suggest that the timing and the context in which FL is administered is equally as important as the direct effects of the cytokine itself on its target cell.
Other soluble factors having hematopoietic effects have recently been applied to the HSCT setting. For example, IL-11 is an important growth factor for thrombopoiesis. 211 Furthermore, IL-11 has been shown to reduce GVHD in allogeneic murine models. 212 Therefore, IL-11 could be potentially used to stimulate platelet recovery, while decreasing the incidence of GVHD in the HSCT recipient. However, such translational application to human allogeneic HSCT has been discouraging, as exemplified by results from one phase I/II study in which IL-11 caused severe fluid retention and multiorgan failure in five patients, resulting in premature study closure. 213 Similar to IL-11, insulin-like growth factor (IGF-1) has been shown to reduce GVHD in allogeneic murine models, while enhancing myeloid and lymphoid progenitor recovery. 214 However, clinical application of IGF-1 in human allogeneic HSCT remains unexplored.
Activation or augmentation of effector cell function. Cytokine therapy directed at cellular activation within the donor or the HSCT recipient may be a useful clinical alternative to ex vivo expansion of effector cell phenotypes. For example, IL-12, 215 IL-15, 216 and IL-18 217 have important roles in influencing NK development and homeostasis as well as in augmenting NK function. Similarly, FL has recently been shown to expand DC precursors in autologous PBSCT recipients which can subsequently be activated with CpG oligodeoxynucleotides to enhance NK and T-cell function. 218 These same cytokines also have direct antitumor effects. [219] [220] [221] [222] Thus, they are attractive candidates for post transplant immunotherapy. For example, IL-15 administration following murine T-cell-depleted BMT significantly increased donor-derived, splenocyte NK reconstitution as well as CD8 þ T cells and NK T cells. 223 Furthermore, T-cell and NK cell functions were enhanced in those transplant recipients receiving IL-15, particularly cytotoxicity and GVL as measured by reduced mortality in lymphoma-inoculated recipients. In addition to enhancing T-cell function, IL-15 has recently been shown to promote in vitro T-cell survival in autologous PB stem cell grafts, 224 providing the benefit of extending effector cell lifespan post transplantation. However, caution with respect to the use of these cytokines in the post transplant setting is warranted, as they play significant roles in acute GVHD 91 and have been shown to exacerbate GVHD in allogeneic Tcell replete BMT recipients. 223, 225 Moreover, combinations of these cytokines (IL-12, -15, and -18) have been shown to exacerbate inflammatory responses 226, 227 and could further promote harmful alloimmune responses and mortality in the HSCT recipient. 228 Soluble factors targeting cellular function might also be used to ameliorate immune dysfunction such as replacing a deficient cellular response directed against residual tumor or infection. For example, soluble factors with known effects in enhancing or mediating NK 229 and T-cell 230 function include IFN-a, IL-2, and IL-7. Specifically, administration of IL-2 and IFN-a in the postautologous transplant setting has been shown to augment NKmediated in vitro cytotoxicity against K562 leukemic cells. 231 Likewise, soluble factors like CD40 ligand (CD40L), TNF-a, IL-4, GM-CSF, and TLR agonists have established roles in DC activation, maturation, and response. 8, 144 For example, use of GM-CSF may prolong antitumor 152 or anti-microbial responses of DC-based vaccines 232 in the HSCT recipient. Similarly, post transplant administration of CpG might augment development and function of reconstituted DCs, 233 further conferring protection against residual disease or infection. 234, 235 Interestingly, function-enhancing factors like CpG have also been shown to increase longevity of effector cells like PMN cells 236, 237 and DCs, 238, 239 making them potential adjuvant therapies for enhancing effector cell recovery and lifespan in the transplant recipient. Finally, CpG motifs could potentially be used to enhance recovery and function of B cells 240 and even incorporated into post-HSCT vaccination regimens to enhance recall and neo-antigen responses. 241 In general, these stimulatory soluble factors have largely been used to augment antitumor responses in the context of MRD following autologous HSCT. [242] [243] [244] Not surprisingly, clinical experience with their use in the allogeneic setting has been disappointing, largely due to their potential to enhance deleterious alloreactivity in the transplant recipient. 245 Inactivation or attenuation of effector cell function. In contrast to their stimulatory effects, soluble factors can also be used to attenuate or to redirect effector cell responses. Historically, MAbs directed against soluble factors have been used to prevent GVHD, 246, 247 to promote GVL, 201 and to redirect T-cell responses. 153, 248 More recently, MAbs directed at T-cell costimulation are being used to induce T-cell anergy and to prevent T-cell alloreactivity. For example, Guinan and colleagues 249 have shown that ex vivo treatment of donor BM with anti-CTLA-4 antibody (disruption of CD28:B7 co-stimulation) significantly decreased the risk of GVHD without affecting hematopoietic reconstitution in haploidentical transplant recipients. Furthermore, using a canine model of nonmyeloablative transplant, Storb et al 250 were able to reduce the dose of tissue-damaging radiation in the preparative regimen through the use of CTLA-4Ig and its inducing T-cell hyporesponsiveness. Similar to CD28:B7 blockade, inhibition of CD154:CD40L interaction has also been shown to induce tolerance 251 and inhibit naı¨ve and primed alloresponses. 252 Finally, an alternative approach for alloreactive T-cell inactivation is insertion of a suicide gene into donor T cells that can be trigged by alloreactivity and induce T-cell apoptosis, thereby attenuating GVHD. 253, 254 Effector cell localization and migration. In order to mediate their anti-microbial and antitumor effects, immune effector cells must travel from the BM and primary lymphoid tissue to sites of antigen capture. Such localization is mediated largely by the interaction of chemotactic factors such as chemokines, integrins, and selectins, and their respective receptors on effector cells. 255 These same migratory factors and pathways are also used by deleterious alloimmune immune cells to localize in tissues such as the lung, where they cause direct cytotoxicity and endorgan damage. 256 Chemokines are chemotactic cytokine-like proteins that influence cell migration and response. [257] [258] [259] In addition to their migratory roles in inflammation, 260 chemokines have important roles in stem cell mobilization 261, 262 and migration, 263 GVHD, 264 and cancer metastases. 265 Given these diverse roles, synthetic chemokine agonists and antagonists are emerging as potential novel agents for localizing or redirecting effector cell responses like antitumor response 266 and deleterious alloreactivity. For example, since CCR7 plays critical roles in DC activation and T-cell migration, 8, 267 antagonists aimed at blocking migration of CCR7-expressing T-cells have been applied in murine models to lessen the effects of chronic GVHD. 268 Similarly, antagonists to CXCR3 and CCR5 have been shown to decrease severity of idiopathic pneumonia syndrome 269 and liver GVHD, 270 respectively. However, chemokine-directed immunotherapy has been shown to have undesirable effects, as in exacerbating GVHD 271, 272 and even sensitizing stem cells to TNF-mediated apoptosis. 273 Therefore, alternative approaches for attenuating T-cell migration and subsequent alloreactive responses such as inhibition of a 4 b 7 integrin 274 expression and downregulation of L-selectin expression with progenipoietin-1 275 may need to be further developed.
Tissue protection and restoration. Soluble factors have also been used for their protective and restorative effects on lymphoid and hematopoietic tissues. For example, FL, 276 keratinocyte growth factor (KGF), 277 and IL-7 278 have been shown to restore lymphopoiesis through their effects on thymic preservation. Furthermore, KGF 279, 280 and FL 210, 281 have been shown to attenuate acute GVHD and even preserve GVL effects. However, caution with their general use in allogeneic HSCT is warranted, as worsening of GVHD has been seen with administration of IL-7 in the context of T-cell replete BM 245 and with FL administration to BMT recipients. 209 Therefore, application of these cytokines in the autologous transplant setting may be more practical and safe. 282, 283 Immunomodulation. In addition to sensing microbial pathogens through recognition receptors like TLRs, innate effector cells also recognize soluble factors derived from damaged or dying cells. 284 Heat shock proteins (HSPs) exemplify one group of 'sterile' inflammatory activators. Acting as intracellular molecular chaperones, HSPs bind and transport antigenic peptides and possess an ability to interact with APCs to induce CTL activation and Th1 responses. 285 Therefore, innate immune receptors recognize a variety of soluble ligands and are uniquely poised to influence subsequent immune responses upon cellular activation. 12 Not surprisingly, synthetic agonists and antagonists of these innate receptor ligands are emerging to modulate immune responses. 235, 286 TLR synthetic agonists such as CpG oligodeoxynucleotides (TLR-9) and imiquimod (TLR-7) are being used as adjuvant therapies to enhance antitumor and anti-microbial responses (reviewed in Ulevitch) 235 . Similarly, the ability of synthetic HSPs to polarize adaptive responses 148, 248 may prove useful in attenuating or even preventing GVHD. 287 Alternatively, manipulations resulting in blunted inflammatory responses might also prove beneficial to allogeneic transplant recipients. For example, mice given sublethal administrations of LPS before being lethally challenged with LPS produce less IL-12p70, IFN-g, and TNF-a than mice not receiving LPS conditioning before lethal LPS challenge. 288 This deactivation in the innate response called endotoxin tolerance can be induced with other TLR agonists including bacterial lipoprotein. 289 In addition to attenuated proinflammatory cytokine production, endotoxin tolerance results in decreased mortality to subsequent infectious challenge. [289] [290] [291] Given their established roles in the pathogenesis of cytotoxic alloimmune reactions in the HSCT recipient, inflammatory cytokines and innate effector cells could be targeted with MAbs to induce a state of immune deactivation that might attenuate deleterious immune responses such as GVHD in the allogeneic HSCT recipient. 246, 292, 293 
Future directions
The use of immunotherapy is fast approaching targeting multiple levels in immune effector response such as: (1) stem and progenitor cells -promoting hematopoietic differentiation using soluble factor augmentation of ex vivo and in vivo expansion; (2) effector cell compartments -preventing or minimizing damage to BM and thymus using mesenchymal stem cells and KGF, respectively; (3) effector cells themselves -augmenting cellular activation, enhancing intracellular signaling pathways and cytokine production, and prolonging effector cell lifespan and responsiveness; and (4) effector cell responses -modulating regulatory cell and cytokine influence on effector cell or its response (autocrine and paracrine pathways), preventing interaction with other effector cells (eg costimulatory blockade), and redirecting effector cell responses. Thus, application of combination immunotherapy to promote desirable (hematopoiesis and IR) and concomitantly to attenuate undesirable responses (cytotoxic alloreactivity that causes GVHD but preserves GVL) in the HSCT recipient may soon be realized (see Table 5 ).
In addition to combination immunotherapy, the potential for selective modulation of host-derived effector cells may also prove useful. That is, studies have shown that host cells including T cells 294 and DCs 50, 53 are present in the early post transplant period. In addition, BM stromal and mesenchymal stem cells remain host in origin for years after successful donor-derived hematopoietic engraftment. 295, 296 In what capacity these host cells influence donor-derived hematopoietic and immune recovery remains to be defined. However, these host-derived immune effector cells do contribute to inflammatory responses in the post transplant period; 53 and their presence has implications with respect to risk for relapse disease 297 and anti-microbial responses. 298 Therefore, further study is warranted to define if hostderived immune cells modulate effects on donor-derived hematopoiesis and immune recovery. If so, successful manipulation and modulation of host effector cells would prove useful in enhancing engraftment, ameliorating cytotoxicity and, ultimately, improving outcome in transplant recipients.
Conclusions
The field of transplant immunology has made significant strides in defining immune effector cell recovery and its underlying role in HSCT. Remarkable progress using this information to manipulate immune recovery following HSCT has been achieved. As our knowledge continues to evolve, so to will our ability to decrease disease-and transplant-related morbidity and mortality using successful immunotherapy in the setting of HSCT.
